8-K: Talphera Reports Q4/FY25 Results, Advances NEPHRO CRRT Study

Talphera, Inc. announced its fourth quarter and full year 2025 financial results, highlighted by 50% enrollment in its NEPHRO CRRT clinical study and a $4.1 million financing tranche.

Summary

• Talphera, Inc. announced financial results for the three and twelve months ended December 31, 2025, along with a corporate update.
• The company achieved 50% enrollment (35 patients) in its 70-patient nafamostat registrational study for CRRT (NEPHRO CRRT clinical study) in March 2026.
• All 12 clinical study sites are now able to enroll patients, supporting an expected study completion later in 2026.
• Talphera closed a $4.1 million third tranche of its March 2025 private placement financing upon reaching the 35-patient enrollment milestone.
• Cash and investments totaled $20.4 million as of December 31, 2025.
• Combined Research & Development (R&D) and Selling, General & Administrative (SG&A) expenses for Q4 2025 were $3.5 million, up from $3.0 million in Q4 2024.
• Net loss attributable to common shareholders for Q4 2025 was $3.8 million, or $0.06 per basic and diluted share, compared to a net loss of $1.9 million, or $0.07 per basic and diluted share, for Q4 2024.
• Full year 2025 net loss was $14.29 million, or $0.34 per basic and diluted share, compared to $13.004 million, or $0.50 per basic and diluted share, for full year 2024.
• Cash operating expenses (SG&A and R&D, excluding stock-based compensation) are projected to be $17 million to $18 million in 2026, an increase from approximately $13 million in 2025, driven by the NEPHRO CRRT study and related expenses.
• A virtual investor and analyst day was scheduled for March 23, 2026, to provide business updates and insights from principal investigators.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses increased, significant progress in the NEPHRO CRRT study and successful financing for it are strong operational positives for a development-stage company, indicating advancement towards commercialization.

Positives

• Achieved 50% enrollment (35 patients) in the NEPHRO CRRT study, a significant milestone for the 70-patient registrational trial.
• All 12 clinical sites are now active and expected to support increased enrollment rates, aiming for study completion in 2026.
• Successfully closed a $4.1 million third tranche of the March 2025 private placement financing, bolstering capital resources.
• Cash and investments balance increased to $20.4 million at December 31, 2025, from $8.863 million at December 31, 2024.
• Niyad has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
• Principal investigators are highly motivated and express dissatisfaction with current CRRT anticoagulants, seeing nafamostat as potentially filling an unmet need.

Negatives

• Net loss attributable to common shareholders for Q4 2025 increased to $3.8 million from $1.9 million in Q4 2024.
• Combined R&D and SG&A expenses for Q4 2025 increased to $3.5 million from $3.0 million in Q4 2024, primarily due to Niyad development costs and certain G&A expenses.
• Full year 2025 net loss increased to $14.29 million from $13.004 million in 2024.
• Expected 2026 cash operating expenses are projected to increase to $17 million-$18 million from approximately $13 million in 2025, indicating higher cash burn.

Risks

• Clinical studies may not be fully enrolled or completed as anticipated.
• Clinical studies may not confirm any safety, efficacy, or other potential developmental product characteristics described or assumed.
• Developmental product candidates may not be beneficial to patients or healthcare providers or be successfully commercialized.
• Inability to obtain regulatory approvals for developmental product candidates.
• Risks related to the ability of Talphera and its business partners to implement development plans, commercial launch plans, forecasts, and other business expectations.
• Risks related to liquidity and the ability to maintain capital resources sufficient to conduct clinical studies.

Future Outlook

Talphera expects cash operating expenses (excluding stock-based compensation) to be in the range of $17 million to $18 million in 2026, an increase from approximately $13 million in 2025. This increase is primarily due to expenses related to finalizing the NEPHRO CRRT registration trial, CMC expenses, and validation batches expected to be incurred prior to the filing of a Premarket Approval (PMA) with the FDA. The NEPHRO CRRT study is expected to be completed later in 2026.

Management Comments

• "Earlier this month, we communicated reaching the 35-patient enrollment mark in the 70-patient nafamostat registrational study for CRRT. Since then, we have added two more target profile clinical sites, and are continuing to enroll patients at a pace to enable completion of the study later this year." Vince Angotti, CEO of Talphera.
• "Our target profile clinical sites and principal investigators remain highly motivated, driving over 90% of enrollment to date, and they are excited by the prospect of having nafamostat potentially approved for use during CRRT, given their dissatisfaction with the current anticoagulants currently being used for CRRT." Vince Angotti, CEO of Talphera.

Industry Context

StockSavvy.ai notes that Talphera operates in the specialty pharmaceutical sector, focusing on critical care therapies. The development of Niyad (nafamostat) for Continuous Renal Replacement Therapy (CRRT) addresses a significant unmet medical need, as current anticoagulants for CRRT are often unsatisfactory for clinicians. The Breakthrough Device Designation from the FDA underscores the potential for Niyad to offer a superior alternative in a market segment where patient safety and efficacy are paramount, potentially positioning Talphera as a key innovator in renal replacement therapy.

Comparison to Industry Standards

• The filing highlights principal investigators' dissatisfaction with current anticoagulants used for CRRT, implying Niyad aims to offer a superior solution compared to existing market options.
• No specific numerical comparisons to other companies' clinical trial enrollment rates or financial performance benchmarks are provided in the filing.

Stakeholder Impact

• Shareholders: Potential positive impact from clinical trial progress and successful financing, but negative impact from increased net loss and projected higher operating expenses.
• Patients: Potential positive impact from the development of Niyad as a potentially superior anticoagulant for CRRT, addressing an unmet medical need.
• Healthcare Providers: Potential positive impact from a new, more effective anticoagulant option for CRRT, addressing dissatisfaction with current treatments.

Next Steps

• Continue enrolling patients in the NEPHRO CRRT clinical study at an increased pace.
• Complete the NEPHRO CRRT study later in 2026.
• Incur expenses related to finalizing the NEPHRO CRRT registration trial, CMC expenses, and validation batches prior to filing a Premarket Approval (PMA) with the FDA.

Key Dates

Recommendation

While the company demonstrates strong operational progress with the NEPHRO CRRT study reaching 50% enrollment and securing associated financing, the increased net loss and projected higher operating expenses for 2026 indicate continued cash burn. The positive clinical developments are balanced by the financial performance, suggesting a 'hold' position until further clarity on commercialization timelines and sustained financial improvement.

Keywords

Talphera, TLPH, NEPHRO CRRT, nafamostat, Niyad, clinical study, anticoagulant, renal replacement therapy, FDA, Breakthrough Device Designation, financial results, Q4 2025, full year 2025, specialty pharmaceutical, R&D, SG&A, net loss, cash and investments, private placement, capital raise